Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024
Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®, on the MediGroup national contract, making it available to all their members in the United States.
FebriDx has been cleared for use in the US by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
MediGroup is the single largest non-acute care group purchasing organization (GPO) in the United States.
Lumos CEO and Managing Director, Doug Ward said:
“We are very pleased to see FebriDx® added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx®.”
Click here to read the ASX Release.
FebriDx has been cleared for use in the US by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
MediGroup is the single largest non-acute care group purchasing organization (GPO) in the United States.
Lumos CEO and Managing Director, Doug Ward said:
“We are very pleased to see FebriDx® added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx®.”
Click here to read the ASX Release.
